Marked Induction of the IAP Family Antiapoptotic Proteins Survivin and XIAP by VEGF in Vascular Endothelial Cells

doi:10.1006/bbrc.1999.1589

Biochemical and Biophysical Research Communications

Volume 264, Issue 3, 2 November 1999, Pages 781-788

https://doi.org/10.1006/bbrc.1999.1589 Get rights and content

Abstract

Vascular endothelial growth factor (VEGF) is a potent angiogenic factor that has been shown to act as an endothelial cell mitogen as well as a vascular permeability factor. Several recent reports have also implicated VEGF as a major survival factor for endothelial cells during angiogenesis and vasculogenesis along with other growth factors such as bFGF and angiopoietin-1. VEGF has been shown to mediate this additional function, at least in part through the induction of bcl-2 and the activation of the PI3 kinase-Akt/PKB signaling pathway. We report here that VEGF can also mediate the induction/upregulation of members of a newly discovered family of antiapoptotic proteins, namely the $I$ nhibitors of $Ap$ optosis (IAP), in vascular endothelial cells. We show that VEGF₁₆₅ leads to the induction of XIAP (2.9-fold) and survivin (19.1-fold) protein in human umbilical vein endothelial cells (HUVECs). In contrast, bFGF had little effect on XIAP expression, but produced approximately a 10-fold induction on survivin. VEGF-dependent upregulation of survivin could be prevented by cell cycle arrest in the G1 and S phases. These findings implicate that the survival and mitotic functions of VEGF in an angiogenic context may be more intrinsically related than previously anticipated. Moreover, they also raise the possibility of therapeutically targeting XIAP or survivin in antiangiogenic therapy as a means of suppressing tumor growth, in addition to directly targeting tumor cells which express these survival proteins.

References (33)

D. Hanahan et al.
Cell
(1996)
M. Klagsbrun et al.
Curr. Biol.
(1993)
P. Carmeliet et al.
Cell
(1999)
H.P. Gerber et al.
J. Biol. Chem.
(1998)
K. Gupta et al.
Exp. Cell Res
(1999)
G. Ambrosini et al.
J. Biol. Chem.
(1998)
L.K. Miller
Trends Cell Biol.
(1999)
A.J. Horrevoets et al.
Blood
(1999)
H.P. Gerber et al.
J. Biol. Chem.
(1998)
G. Neufeld et al.
FASEB J.
(1999)

L.E. Benjamin et al.

J. Clin. Invest.

(1999)

T. Alon et al.

Nature Med.

(1995)

L.E. Benjamin et al.

Proc. Natl. Acad. Sci. USA

(1997)

J.E. Nor et al.

Am. J. Pathol.

(1999)

P. Liston et al.

Nature

(1996)

E.C. LaCasse et al.

Oncogene

(1998)

Cited by (308)

Context dependent role of p53 during the interaction of hepatocellular carcinoma and endothelial cells
2022, Microvascular Research
During the progression of hepatocellular carcinoma (HCC), several angiogenic factors are overexpressed in the hepatic microenvironment, which play a critical role in governing the phenotype of the endothelial cells. Mutation in the p53 gene (TP53) is a common event in HCC that may dysregulate the angiogenic signals. However, their functional messages remain largely unexplored at the onset of metastasis.
Role of p53 was studied by siRNA mediated silencing of p53 in HepG2 cells (WTp53), collecting and analyzing their conditioned medium, followed by indirect co-culture with endothelial cells (HUVECs). Gene and protein expression in HCC cells and endothelial cells was studied by RT-qPCR and western blotting respectively. β-catenin protein expression and localization were analyzed by immunocytochemistry.
We have studied a cell-to-cell interaction model to investigate the crosstalk of endothelial and hepatoma cells by either knocking down p53 or by using p53 null low metastatic HCC cell line. In the absence of p53, the HCC cells influence the migration and vascular network formation of endothelial cells through paracrine signaling of VEGF. Secretory VEGF activated the VEGF receptor-2 along with the survival signaling in endothelial cells. However, the β-catenin signal is upregulated in endothelial cells only during interaction with metastatic set up irrespective of absence and presence of p53, indicating context-dependent participation of p53 during communication between hepatoma cells and endothelial cells.
This study highlights that the role of p53 on cellular responses during interaction of hepatocellular carcinoma and endothelial cells is distinct to cell types and context.
Snake venom vascular endothelial growth factors (svVEGFs): Unravelling their molecular structure, functions, and research potential
2021, Cytokine and Growth Factor Reviews
Vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis, a physiological process characterized by the formation of new vessels from a preexisting endothelium. VEGF has also been implicated in pathologic states, such as neoplasias, intraocular neovascular disorders, among other conditions. VEGFs are distributed in seven different families: VEGF-A, B, C, D, and PIGF (placental growth factor), which are identified in mammals; VEGF-E, which are encountered in viruses; and VEGF-F or svVEGF (snake venom VEGF) described in snake venoms. This is the pioneer review of svVEGF family, exploring its distribution among the snake venoms, molecular structure, main functions, and potential applications.
The Multiple Roles of the IAP Super-family in cancer
2020, Pharmacology and Therapeutics
The Inhibitor of Apoptosis proteins (IAPs) are a family of proteins that are mainly known for their anti-apoptotic activity and ability to directly bind and inhibit caspases. Recent research has however revealed that they have extensive roles in governing numerous other cellular processes. IAPs are known to modulate ubiquitin (Ub)-dependent signaling pathways through their E3 ligase activity and influence activation of nuclear factor κB (NF-κB). In this review, we discuss the involvement of IAPs in individual hallmarks of cancer and the current status of therapies targeting these critical proteins.
Nanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs
2017, Advanced Drug Delivery Reviews
Citation Excerpt :
Ryan et al. demonstrated that survivin is an attractive target for anti-cancer therapy because of its role in poor prognosis and aggressiveness of the tumors [137]. Survivin enhances angiogenesis, the mechanism which is likely to be related to its ability to inhibit apoptosis in endothelial cells, thereby enhancing cell survival [138–140]. Furthermore, increased expression of survivin has also been found to confer resistance to chemotherapy [141,142].
Anticancer therapy has always been a vital challenge for the development of nanomedicine. Repeated single therapeutic agent may lead to undesirable and severe side effects, unbearable toxicity and multidrug resistance due to complex nature of tumor. Nanomedicine-based combination anticancer therapy can synergistically improve antitumor outcomes through multiple-target therapy, decreasing the dose of each therapeutic agent and reducing side effects. There are versatile combinational anticancer strategies such as chemotherapeutic combination, nucleic acid-based co-delivery, intrinsic sensitive and extrinsic stimulus combinational patterns. Based on these combination strategies, various nanocarriers and drug delivery systems were engineered to carry out the efficient co-delivery of combined therapeutic agents for combination anticancer therapy. This review focused on illustrating nanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs for synergistically improving anticancer efficacy.
Pleiotropic effects of survivin in vascular endothelial cells
2016, Microvascular Research
Citation Excerpt :
Although minimally expressed in normal adult tissues, SVV is highly expressed in embryonic tissues and various types of human cancers, and its expression is correlated with poor cancer prognosis (Altieri, 2001; Balakier et al., 2013; Hoffman et al., 2002). In vascular endothelial cells, SVV expression is significantly boosted in response to platelet-derived growth factor (PDGF), VEGF, angiopoietin, as well as vascular injury (Blanc-Brude et al., 2002; Papapetropoulos et al., 2000; Tran et al., 1999). Functionally, SVV stimulates endothelial cell proliferation while inhibiting apoptosisin endothelial cells (Blanc-Brude et al., 2002).
To assess the effects of survivin (SVV)in vascular endothelial cells.
In this study, we applied a gain-of-function approach and ectopically expressed SVV in rat aortic endothelial cells (RAECs) using a SVV-expressing adenovirus. The resulting SVV expression on the steady-state mRNA and protein level in RAECs was determined by reverse transcription quantitative PCR and Western blot, respectively. Cell viability, apoptosis, and migration were assessed in vitro by CCK-8 assay, flow cytometry, and transwell assay, respectively. The effect of SVV on in vivo angiogenesis was evaluated by immunohistochemistry in nude mice. Non-infected RAECs and those infected with GFP-expressing control adenovirus were used as controls.
Compared to non-infected or control adenovirus-infected RAECs in vitro, SVV-expressing cells had increased viability and migratory capability, but reduced apoptosis. In vivo, SVV-expressing RAECs were associated with a higher level of angiogenesis.
SVV is a positive regulator of endothelial cell survival and migration, and thus, stabilizes endothelial cells and stimulates angiogenesis.
Lymphangioleiomyomatosis (LAM): Molecular Insights into mTOR Regulation Lead to Targeted Therapies
2016, Molecules to Medicine with mTOR: Translating Critical Pathways into Novel Therapeutic Strategies
Lymphangioleiomyomatosis (LAM) is a multisystem disease occurring primarily in women that is characterized by lung destruction, renal tumors (angiomyolipomas), and lymphatic involvement. LAM is associated with proliferation of the neoplastic LAM cell, which has mutations/loss of function of the tumor suppressor genes, tuberous sclerosis complex TSC1 or TSC2. Because of the loss of TSC1/TSC2 function, LAM cells exhibit constitutively active mammalian/mechanistic target of rapamycin, with effects on cell proliferation, cell size, autophagy, and other critical biological processes. Rapamycin slows the progression of LAM disease, but appears not to cause LAM cell death. The combination of rapamycin and one (or more) other treatments are being tested for effects on LAM cell migration, invasiveness, and viability.

View all citing articles on Scopus

¹: To whom correspondence should be addressed. Fax: (416) 480-5703. E-mail: [email protected].

View full text

Regular ArticleMarked Induction of the IAP Family Antiapoptotic Proteins Survivin and XIAP by VEGF in Vascular Endothelial Cells

Abstract

Cell

Curr. Biol.

Cell

J. Biol. Chem.

Exp. Cell Res

J. Biol. Chem.

Trends Cell Biol.

Blood

J. Biol. Chem.

FASEB J.

J. Clin. Invest.

Nature Med.

Proc. Natl. Acad. Sci. USA

Am. J. Pathol.

Nature

Oncogene

Regular Article
Marked Induction of the IAP Family Antiapoptotic Proteins Survivin and XIAP by VEGF in Vascular Endothelial Cells